Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yaoyu, Li, Shaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916637/
https://www.ncbi.nlm.nih.gov/pubmed/24516334
http://dx.doi.org/10.2147/OTT.S41786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916637/
https://www.ncbi.nlm.nih.gov/pubmed/24516334
http://dx.doi.org/10.2147/OTT.S41786

Ejemplares similares